The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression
- 23 April 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer and Metastasis Reviews
- Vol. 32 (3-4), 535-551
- https://doi.org/10.1007/s10555-013-9423-y
Abstract
The most common ovarian cancer is epithelial ovarian cancer (EOC) characterised by few early symptoms, widespread peritoneal dissemination and ascites at advanced stages that result in poor prognosis. Despite the recent progress in its management, including surgery and chemotherapy, EOC remains the most lethal gynaecological malignancy in women. Due to the limitations of current therapeutic approaches, many patients die of secondary disease (metastasis). MUC1 is associated with cellular transformation and tumorigenicity and is considered as an attractive therapeutic target for cancer therapy owning to its over-expression in most adenocarcinomas including EOC. Tumour-associated MUC1 plays an important role in EOC metastasis and progression. In neoplastic tissues, MUC1 is underglycosylated and reveals epitopes that are masked in the normal cells. This feature makes it possible to target tumour-associated MUC1 with antibodies, toxins or radionuclides or use a vaccine targeting tumour-associated MUC1 antigen. The shed tumour-associated MUC1 in blood can be used as a diagnostic biomarker for EOC detection and monitoring. Our recent results have shown that over-expression of MUC1 plays a very important role in EOC progression and MUC1 is an ideal target for targeted therapy to control metastatic and recurrent EOC. This review will summarize some important new findings supporting the role of MUC1 in EOC metastasis and progression and focus on the MUC1-based targeted therapy for control of metastatic and recurrent EOC.Keywords
This publication has 97 references indexed in Scilit:
- Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening TrialCancer, 2011
- Potential Markers for Detection and Monitoring of Ovarian CancerJournal of Oncology, 2011
- MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transitionOncogene, 2010
- Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma CellsCancer Research, 2009
- Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor CellsChemBioChem, 2009
- Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumoursEuropean Journal Of Cancer, 2009
- Phototoxic aptamers selectively enter and kill epithelial cancer cellsNucleic Acids Research, 2008
- Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancerHistochemistry and Cell Biology, 2008
- Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gainBritish Journal of Cancer, 2007
- WNT and β-catenin signalling: diseases and therapiesNature Reviews Genetics, 2004